Form 4: STAAR Surgical Director Lilian Y. Zhou Granted Stock Options as Part of Compensation Program

STAAR Surgical Co. Director Lilian Y. Zhou was granted 4,363 stock options with an exercise price of $16.72 as part of her annual non-employee director equity compensation.

Summary

• Lilian Y. Zhou, a Director and Chair of the Capital Stewardship Committee at STAAR Surgical Co. (STAA), was granted 4,363 stock options.
• The options were granted on June 25, 2025, with an exercise price of $16.72 per share.
• These stock options will vest quarterly, with 1/4 of the shares vesting on September 25, 2025, December 25, 2025, March 25, 2026, and June 25, 2026.
• The options have an expiration date of June 24, 2035.
• This grant is part of the Corporation's annual non-employee director equity compensation program for her service as the Chair of the Capital Stewardship Committee.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine insider compensation filing, which is generally a positive sign of aligning director interests with shareholders, but it provides no new operational or financial news that would significantly alter sentiment.

Positives

• The grant of stock options aligns the interests of Director Lilian Y. Zhou with those of shareholders, as the options gain value if the stock price increases above the exercise price.
• The equity compensation program helps attract and retain qualified non-employee directors, contributing to strong corporate governance.

Risks

• The value of the granted stock options is dependent on the future performance of STAAR Surgical Co.'s stock price; if the stock price does not exceed the exercise price of $16.72, the options may not be profitable.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Management Comments

• The filing indicates that the equity awards were granted to the Reporting Person on June 25, 2025, pursuant to the Corporation's annual non-employee director equity compensation program for service as the Chair of the Capital Stewardship Committee.

Industry Context

This filing is a routine insider transaction disclosure and does not provide specific insights into broader industry trends within the medical device sector. However, the practice of providing equity compensation to non-employee directors is a standard corporate governance practice across many industries to align leadership incentives with shareholder value.

Comparison to Industry Standards

• The grant of stock options as part of non-employee director compensation is a common practice in publicly traded companies, including those in the medical device sector.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar size and market capitalization, though this document does not provide such comparative data.
• Companies like Alcon, Bausch + Lomb, and Johnson & Johnson (through its medical device segment) commonly utilize equity-based compensation for their directors to incentivize long-term performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, as the options' value is directly tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The granted stock options will vest in four equal quarterly installments on September 25, 2025, December 25, 2025, March 25, 2026, and June 25, 2026.
• Lilian Y. Zhou will continue her service as a Director and Chair of the Capital Stewardship Committee for STAAR Surgical Co.

Key Dates

Keywords

STAAR Surgical, STAA, SEC Form 4, Stock Options, Equity Compensation, Director Compensation, Lilian Y. Zhou, Insider Transaction